《Oncology, Geriatrics, and others》
Part I - Chemotherapy
1
General Guidelines for Chemotherapy Dosage Based on Hepatic Function
1.1
Recommended Dose Reduction for Hepatic Dysfunction
Part II - Oncology
2
Prostate Cancer
2.1
Staging System for Prostate Cancer
2.1.1
Definitions for T, N, M - prostate cancer
2.1.2
AJCC Prognostic Groups - prostate cancer
2.2
Diagnosis - prostate cancer
2.2.1
Initial Prostate Cancer Diagnosis
2.2.2
Initial Risk Stratification and Staging Workup - Prostate Cancer
2.3
Treatment - prostate cancer
2.3.1
Systemic Therapy for Castration-Naive Prostate Cancer
2.3.2
Systemic Therapy for M0 Castration-Resistant Prostate Cancer (CRPC)
2.3.3
Systemic Therapy for M1 Castration-Resistant Prostate Cancer (CRPC)
2.4
Principles of Genetics - prostate cancer
2.4.1
Germline Testing
2.4.2
Somatic Tumor Testing
2.5
Principles of Imaging - prostate cancer
2.5.1
Goals of Imaging
2.5.2
Efficacy of Imaging
2.5.3
Plain Radiography
2.5.4
Ultrasound
2.5.5
Bone Imaging
2.5.6
Computed Tomography
2.5.7
Magnetic Resonance Imaging
2.5.8
Positron Emission Tomography (PET)
2.6
Principles of Active Surveillance and Observation
2.6.1
Advantages of active surveillance:
2.6.2
Disadvantages of active surveillance:
2.6.3
Advantages of observation:
2.6.4
Disadvantages of observation:
2.7
Principles of Radiation Therapy
2.8
Principles of Surgery
2.9
Principles of Androgen Deprivation Therapy
2.9.1
ADT for Clinically Localized (N0,M0) Disease
2.9.2
ADT for Regional (N1,M0) Disease
2.9.3
ADT for pN1 Disease
2.9.4
ADT for M0 PSA Persistence/Recurrence After RP or EBRT (ADT for M0 Castration-Naïve Disease)
2.9.5
ADT for Metastatic Castration-Naïve Disease
2.9.6
Secondary Hormone Therapy for M0 or M1 CRPC
2.10
Part III - Geriatrics
Part IV - Others
3
ICD 10 CM
3.1
國際疾病分類第十版中英對照檢索
4
TFDA ATC
4.1
藥品藥理治療分類 ATC Code
5
TFDA AHFS/DI
5.1
藥品藥理治療分類 AHFS/DI Code
6
Frequently Used Links
6.1
醫藥參考
6.2
藥物辨識
7
Memo
7.1
Daily
7.2
Code
4
TFDA ATC
Anatomical Therapeutic Chemical Classification
4.1
藥品藥理治療分類 ATC Code